A bond you can count on

We are a CRO based at the heart of the Barcelona Science Park. With more than 20 years of experience in chemistry services, we provide contract research and development services in Medicinal Chemistry, Chemical R&D and Solid State R&D.

Contact us to find out how our expertise in Cocrystals and Asymmetric Synthesis can help your project succeed, now also for Highly Potent Compounds too.

A bond you can count on

We are a CRO based at the heart of the Barcelona Science Park. We specialise in Medicinal Chemistry, Chemical R&D and Solid State R&D.

Contact us to find out how our expertise in Cocrystals and Asymmetric Synthesis can help your project succeed, now also for High Potent Compounds too.

Our Services

Medical Chemistry Enantia Barcelona


Our Medicinal Chemistry team has a solid background in the design and synthesis of small molecules as ligands for a broad range of therapeutic targets.
We can contribute in the different stages of your drug discovery program.

Learn more

Chemical and process Enantia


Chemistry that works. We work in the resolution of chemical challenges, the design of new routes of synthesis and their impurity profiling, resulting in the creation of valuable processes for fine chemical, pharma and biotech industry.

Learn more

Solid State R&D

Solid State

Crystallising your ideas. We can help you through the entire process of solid form selection, from the initial screening, analysis, characterisation and performance tests, to its development, scale-up and long-time stability tests.

Learn more

Our History

  • Flow chemistry now available at Enantia for process chemistry and medicinal chemistry
    2024 Flow Chemistry

    New flow chemistry capacities at Enantia

    Flow chemistry is now available at Enantia for medicinal chemistry and CMC development services.
    This will complement our 20 years of experience in batch and semi-batch chemistry to develop sustainable, safe and efficient chemical processes.
  • Enantia celebrates 20th years of providing chemistry services

    Enantia celebrates 20 years of excellence in chemical services

    Enantia is commemorating its 20th anniversary this year, marking two decades of dedication to excellence in chemistry and innovation.
    Since our inception in 2003, Enantia has been providing cutting-edge solutions to the pharmaceutical, biotech, and material industries by offering a comprehensive suite of services encompassing medicinal chemistry, CMC development, solid form R&D, and more.

  • HAPI facilities

    New Highly Potent API (HAPI) laboratory commissioning

    Enantia can now work with highly potent compounds too in solid form screening and solid form development projects, thanks to our new specific equipment for HAPIs.
  • Pharmaceutical cocrystal development of Seglentis

    Seglentis approved by the FDA

    Seglentis, a new API-API pharmaceutical cocrystal discovered at Enantia for ESTEVE Pharmaceuticals is approved by the FDA.
  • Kilolab for process chemistry and scale-up services at Enantia

    New Kilolab

    Enantia commissions a new Kilo Lab for the development, scale up and production of key intermediates and preclinical compounds.
  • CBD and THC

    Cannabinoid cocrystal platform

    Enantia consolidates its proprietary technologies to provide the marketplace with high quality synthetic cannabinoids, and the licensing of our cocrystallization technology to purify CBD, THC and other minor cannabinoids from natural extracts.
  • 2018

    Enantia’s 15th anniversary

    In 2018 Enantia celebrates its 15th anniversary.
    Furthermore, during 2018 Enantia opens its new offices in the Barcelona Science Park, which consolidate the growth of the company over the years.
  • 2016

    Patent Milestone: 50

    During 2016 Enantia filed its 50th patent.

  • 2015

    Licensing of Esteve and Mundipharma

    An innovative cocrystal, obtained by Enantia working in collaboration with Esteve R&D, is part of the global partnership announced by Esteve and Mundipharma-Purdue.

  • 2014

    Collaboration with the ALBA Synchrotron light

    Start of the ALBA synchrotron collaboration, the most important light facility in the south of Europe.

    Since 2014, here at Enantia we have taken advantage of the ALBA’s light beam, allowing us to reach even higher resolution and greater sensitivity. With the in house diffractometer we are already able to characterise a crystaline structure, however with the ALBA beamline we are able to tackle the most challenging projects.

    The same year we celebrated filing our 40 th patent.

  • 2013

    European consortium Nano3Bio

    Enantia enters in the Nano3Bio’s international scientific project in the field of biotechnology. Its goal is the breakthrough from basic research to biotechnological production of chitosans. The consortium represents eight countries (six universities, two research centres, 13 start-up or well established SMEs and one large company).

  • 2012

    New commercial office in Italy

    Enantia opens its first commercial office in Milan (Italy) and starts its Medicinal ChemistryDepartment.

  • 2011

    Senén Vilaró Prize

    The company is awarded the 2011 Senén Vilaró Prize. The Bosch i Gimpera Foundation (University of Barcelona) gives this prize as a recognition of Enantia’s track record in transferring its scientific and technical knowledge back to society.

  • 2010

    Enantia, selected by Neogenius as preferred partner

    Set up on the basis of a strategic alliance between four pharmaceutical companies (Almirall, Esteve, Palau Pharma and Proteomika), the Neogenius project kicks off and runs for four years with a total budget of 15.4 million euros with the objective to discover and develop new painkilling medicines for patients suffering from osteoarthritis.

    Enantia is selected as custom synthesis provider to support the drug discovery activities of the consortium.

  • 2009

    Patent Milestone: 20

    Enantia files its 20th patent.

  • 2008

    Pimec Prize for the most competitive company

    Enantia is awarded the 2008 Pimec Prize (Premis Pimec) for the most competitive small company. This prize was given personally by the King of Spain Juan Carlos I to the then CEO Llorenç Rafecas during a dinner in Barcelona. Pimec is the association that represents the micro, small and medium-sized companies in Catalonia.

  • 2007

    New Crystal Engineering Department

    Enantia opens its third laboratory in Esplugues de Llobregat to start its Crystal Engineering Department. The activity of our Solid Form Department is the screening and development of new cocrystals, polymorphs, salts, solvates and amorphous forms.

  • 2006

    CENIT R&D project

    Genius Pharma, a consortium led by the three major Spanish pharmaceutical companies in which Enantia plays one of the leading roles, wins a CENIT R&D project (CDTI). The main objective of the project is to develop, build and exploit technology platforms and best practices in the drug discovery process.

  • 2004

    Inauguration of the second lab

    Enantia opens a second laboratory dedicated to synthesis.

  • 2003

    Success in tech transfer

    Enantia is created as a spin-off of the University of Barcelona with headquarters in the Barcelona Science Park. The initial team is composed of eight people including Mr. Llorenç Rafecas as CEO, a professional with 24 years of experience in the fine chemicals industry, with executive responsibilities in chemical R&D.